#ASCO19: Merck’s PD-1 star Keytruda illustrates just how powerful it can be over 5 years — with plenty of room for improvement
CHICAGO — Merck took center stage at a muted ASCO Saturday morning opening with its impressive 5-year update on what Keytruda has done for lung cancer patients. The PD-1 more than quadrupled the survival rate of patients with non-small cell lung cancer who had not been previously treated with chemo — jumping from earlier grim expectations of a 5.5% 5-year survival rate to 23.2%.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,100+ biopharma pros reading Endpoints daily — and it's free.